Cost-effectiveness of brentuximab vedotin compared with conventional chemotherapy for relapsed or refractory classic Hodgkin lymphoma in China

Cost-effectiveness of brentuximab vedotin compared with conventional chemotherapy for relapsed or refractory classic Hodgkin lymphoma in China

Abstract Background Relapsed or refractory classic Hodgkin lymphoma (RRcHL) associates with poor prognosis and heavy disease burden to patients. This study evaluated the cost-effectiveness of brentuximab vedotin (BV) in comparison to conventional chemotherapy in patients with RRcHL, from a Chinese h...

Full description

Bibliographic Details
Main Authors: Shitong Xie, Yanan Sheng, Ling-Hsiang Chuang, Jing Wu
Format: Article
Language:English
Published: BMC 2024-06-01
Series:Health Economics Review
Subjects:
Relapsed or refractory classic Hodgkin lymphoma
Brentuximab vedotin
Cost-effectiveness analysis
Cost-utility analysis
Chemotherapy
China
Online Access:https://doi.org/10.1186/s13561-024-00514-6

Internet

https://doi.org/10.1186/s13561-024-00514-6

Similar Items